| Revision as of 05:21, 31 July 2011 editArcadian (talk | contribs)163,050 edits added Category:Experimental cancer drugs using HotCat← Previous edit |
Latest revision as of 17:24, 5 February 2023 edit undoOzzie10aaaa (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers214,346 editsm Cleaned up using AutoEd |
| (15 intermediate revisions by 11 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{drugbox |
|
|
|
{{one source|date=August 2014}} |
| ⚫ |
| verifiedrevid = 400278734 |
|
|
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
⚫ |
| verifiedrevid = 447729255 |
|
⚫ |
| image = Mertansine mab structure.svg |
|
|
<!-- Monoclonal antibody data --> |
|
| type = mab |
|
| type = mab |
| ⚫ |
| image = Mertansine mab structure.svg |
|
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = ] v6 |
|
| target = ] v6 |
|
|
<!-- Clinical data --> |
| ⚫ |
| CAS_number = |
|
|
|
| tradename = |
|
⚫ |
| pregnancy_AU = |
|
⚫ |
| pregnancy_US = |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_AU = |
|
⚫ |
| legal_CA = |
|
⚫ |
| legal_UK = |
|
⚫ |
| legal_US = |
|
⚫ |
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
|
<!-- Pharmacokinetic data --> |
|
|
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
<!-- Identifiers --> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
⚫ |
| CAS_number = |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
| ⚫ |
| chemical_formula = |
|
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ⚫ |
| molecular_weight = |
|
|
| bioavailability = |
|
| ChemSpiderID = none |
|
|
<!-- Chemical data --> |
| ⚫ |
| protein_bound = |
|
|
⚫ |
| chemical_formula = |
| ⚫ |
| metabolism = |
|
|
⚫ |
| molecular_weight = |
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_AU = |
|
| ⚫ |
| pregnancy_US = |
|
| ⚫ |
| pregnancy_category = |
|
| ⚫ |
| legal_AU = |
|
| ⚫ |
| legal_CA = |
|
| ⚫ |
| legal_UK = |
|
| ⚫ |
| legal_US = |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
'''Bivatuzumab mertansine''' is a combination of ], a ]d ], and ], a ]. It is designed for the treatment of ].<ref>{{cite journal|doi=10.1158/1078-0432.CCR-06-0910|pmid=17062682|year=2006|last1=Tijink|first1=BM|last2=Buter|first2=J|last3=De Bree|first3=R|last4=Giaccone|first4=G|last5=Lang|first5=MS|last6=Staab|first6=A|last7=Leemans|first7=CR|last8=Van Dongen|first8=GA|title=A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus|volume=12|issue=20 Pt 1|pages=6064–72|journal=Clinical cancer research : an official journal of the American Association for Cancer Research}}</ref> |
|
'''Bivatuzumab mertansine''' is a combination of ], a ], and ], a ]. It is designed for the treatment of ].<ref>{{cite journal | vauthors = Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA | display-authors = 6 | title = A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus | journal = Clinical Cancer Research | volume = 12 | issue = 20 Pt 1 | pages = 6064–72 | date = October 2006 | pmid = 17062682 | doi = 10.1158/1078-0432.CCR-06-0910 | doi-access = free }}</ref> |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
| Line 37: |
Line 50: |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |